Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Thomas Olencki"'
Autor:
Elizabeth A. Streacker, Thomas Olencki, Volodymyr Karpa, Kala M. Levine, William E. Carson, Lorena P. Suarez-Kelly, Joseph Markowitz, Sara E. Martin del Campo, Taylor R. Brooks, Kari Kendra, Anissa Bingman, Susan Geyer
Publikováno v:
Cancer Immunology, Immunotherapy
Melanoma is a highly immunogenic tumor and consequently, efforts have been centered on the development of immune-based treatments for this malignancy [1]. Interferons were initially described in the mid-1950s as proteins that interfere with viral rep
Publikováno v:
Current Problems in Cancer. 46:100805
Patient survival with renal cell carcinoma (RCC) has improved with the use of molecular targeted agents and immunotherapy. Given the potential activity of these agents in treating brain metastases, the role of aggressive local management with surgery
Autor:
Evan J. Lipson, Ragini R. Kudchadkar, Sunil Reddy, Tomoko Akaike, Thomas Olencki, William H. Sharfman, Philip Friedlander, Steven P. Fling, Mizuho Kalabis, Candice D. Church, Kari Kendra, Michi M. Shinohara, Adil Daud, Adam I. Riker, Harriet M. Kluger, Elad Sharon, Melissa Amber Burgess, Janis M. Taube, Paul Nghiem, Brent A. Hanks, Suzanne L. Topalian, Blanca Homet Moreno, Andrew S. Brohl, Brian C. Boulmay, Martin A. Cheever, Bob Salim, Erin Jensen, Shailender Bhatia, Nirasha Ramchurren
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Journal for immunotherapy of cancer, vol 9, iss 4
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 9, iss 4
Journal for Immunotherapy of Cancer
BackgroundMerkel cell carcinoma (MCC) is an aggressive skin cancer associated with poor survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of durable tumor regression compared with chemotherapy for MCC. The current stud
Autor:
Darren R. Feldman, Toni K. Choueiri, Joel Picus, Ben L. Sanford, Olwen Hahn, M. Dror Michaelson, Shaker R. Dakhil, Daniel J. George, Meghara K. Walsh, Thomas Olencki, Eric J. Small, Susan Halabi, Michael J. Morris
Publikováno v:
Journal of Clinical Oncology. 35:591-597
Purpose Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell carcinoma (mRCC). This randomized phase II multicenter trial evaluated cab
Autor:
Amanda Campbell, Akaansha Ganju, Stephen V. Liu, Sarvani Uppati, Kala M. Levine, Bonnie Paul, Tiffany Noel, Elizabeth L. McMichael, Gonzalo N. Olaverria Salavaggione, Panos Savvides, William E. Carson, Melanie E. Davis, Lakhvir S. Atwal, Michael A. Caligiuri, Theodoros N. Teknos, Nicholas B. Courtney, Thomas Olencki, Kallan Williams, Megan C. Duggan, Brooke Benner, Susheela Tridandapani, Kyle A. Martin, Xiaokui Mo, John C. Byrd
Publikováno v:
Clin Cancer Res
Purpose: mAbs including cetuximab can induce antibody-dependent cellular cytotoxicity (ADCC) and cytokine production mediated via innate immune cells with the ability to recognize mAb-coated tumors. Preclinical modeling has shown that costimulation o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66fcefe11987d7a560074b271108d065
https://europepmc.org/articles/PMC6697573/
https://europepmc.org/articles/PMC6697573/
Autor:
Kimberly D Allman, Amir Mortazavi, Nancy B. Davis, Moshe Chaim Ornstein, Jorge A. Garcia, Brian P. Hobbs, Brian I. Rini, Timothy D. Gilligan, W. Kimryn Rathmell, Laura S. Wood, Xuefei S Jia, Sumanta K. Pal, Allison Martin, Thomas Olencki, Jackie M Tomer
Publikováno v:
The Lancet. Oncology. 20(10)
Summary Background Checkpoint inhibitor therapy is a standard of care for patients with metastatic renal cell carcinoma. Treatment options after checkpoint inhibitor therapy include vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase
Autor:
Martin A. Cheever, Steven P. Fling, Blanca Homet Moreno, Nirasha Ramchurren, Andrew S. Brohl, Thomas Olencki, Shailender Bhatia, Evan J. Lipson, William H. Sharfman, Kim Margolin, Lisa Lundgren, Brian C. Boulmay, Harriet M. Kluger, Candice D. Church, Melissa Amber Burgess, Michi M. Shinohara, Suzanne L. Topalian, Bob Salim, Song Youn Park, Janis M. Taube, Paul Nghiem, Sunil Reddy, Nageatte Ibrahim, Steven R. Bird, Ragini R. Kudchadkar, Adam I. Riker, Abha Soni, Brent A. Hanks, Elad Sharon, Adil Daud, Phillip A. Friedlander
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 37, iss 9
PURPOSE Merkel cell carcinoma (MCC) is an aggressive skin cancer often caused by the Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for advanced MCC (aMCC) demonstrate increased progression-free survival (PFS)
Autor:
Xueliang Pan, Gregory B. Lesinski, Jeffrey Schlom, Renee N. Donahue, Thomas Olencki, Jacob Richards, Taylor R. Brooks, Volodymyr Karpa, Bonnie Paul, William E. Carson, Caroline Jochems, Megan C. Duggan, Elizabeth Foust, Susheela Tridandapani
Publikováno v:
Cancer Immunology, Immunotherapy. 65:1353-1364
Prime-boost vaccination with recombinant (r) vaccinia(V)-CEA(6D)-TRICOM (triad of co-stimulatory molecules B7.1, ICAM-1 and LFA-3) and rFowlpox(F)-CEA(6D)-TRICOM infect antigen-presenting cells and direct expression of co-stimulatory molecules. We hy
Autor:
Harry A. Drabkin, Leonard Joseph Appleman, Robert J. Motzer, Sergio Bracarda, Frederic Rolland, Daniel A. Vaena, Stéphane Oudard, Thomas Powles, Toni K. Choueiri, Jillian Youkstetter, Daniel Castellano, Bernard Escudier, Osvaldo Arén Frontera, Thomas Olencki, Steven Milwee, Piotr Tomczak, Julie C. Lougheed
Purpose Cabozantinib, an inhibitor of tyrosine kinases including MET, vascular endothelial growth factor receptors, and AXL, increased progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in patients with advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9341f38ae59e7700a00cd55bf48c0cae
https://europepmc.org/articles/PMC6804840/
https://europepmc.org/articles/PMC6804840/
Autor:
Darren R. Feldman, Milan Mangeshkar, M. Dror Michaelson, Shaker R. Dakhil, Ben L. Sanford, Daniel J. George, Meghara K. Walsh, Thomas Olencki, Joel Picus, Susan Halabi, Colin Hessel, Toni K. Choueiri, Olwen Hahn, Michael J. Morris, Christian Scheffold, Eric J. Small
Publikováno v:
European journal of cancer (Oxford, England : 1990)
Background The randomised phase 2 CABOSUN trial comparing cabozantinib with sunitinib as initial therapy for advanced renal cell carcinoma (RCC) of intermediate or poor risk met the primary end-point of improving progression-free survival (PFS) as as